InvestorsHub Logo
Followers 67
Posts 1293
Boards Moderated 0
Alias Born 08/12/2014

Re: tryn2 post# 332704

Monday, 11/23/2020 10:57:29 PM

Monday, November 23, 2020 10:57:29 PM

Post# of 701121
I am with you brother. My share counts only increase with days passing by, peaking each passing week.

For a usual small development stage biotech company with a binary event coming, I would normally sell enough so that I could play with house money. I have done that before, but not this time with this stock.

The reason, as I said repeatedly, is we are actually not faced with a binary event anymore since the adaptation of the endpoints were revealed in EU clinicaltrial registry, specifically UK and Germany.

Then based on the blinded, blended data and the subsequent uptrend updated data, it's obvious the primary endpoint is met;

With the knowledge we have known about this disease and its standard of care treatment and outcomes, as well as various numerous failed Phase 3 clinical trials and the FDA approved Optune device, it would be highly likely at least one key second endpoint out of the five second endpoints will be met, which will be a support enough for FDA approval based on both safety and efficacy.

Because the endpoints the statisticians and the company and its experts are analyzing are numerous and complex compared to that of a usual trial, and because Linda Powers is ambitious, capable who is not a normal CEO who would just take anything which can normally be given, we may see a big surprise when everything is settle.

It's tough to hold all the shares but selling some at around $1-$2 is just out of the question.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News